noom glp 1 Launches GLP-1 Microdosing for Longevity Noom introduces longevity-focused GLP-1 microdosing
Description
Jessica Drummond 00:53:20 Thank you so much for joining me today for this episode of the Integrative Womens Health Podcast
Glucagon-like peptide-1 (GLP-1) receptor agonists are licensed for type 2 diabetes and weight management, not inflammatory conditions
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, meaning it mimics the role of the naturally produced GLP-1 hormone that regulates feelings of fullness after eating
If you are taking any GLP-1 medication, you should proactively address constipation rather than waiting for it to become a problem
Conclusion GLP1 receptor agonists represent a promising advancement in the management of PCOS, especially for women who struggle with obesity and insulin resistance
A 2024 study suggests injectable semaglutide leads to more weight loss in real-world settings
